DCK and neoplasm: Based on the importance of the biomarkers involved in gemcitabine metabolism, we assessed the expressions of three key molecules (hENT1, dCK, and RRM1) in tumor samples from 28 patients with advanced BTC who received first-line gemcitabine monotherapy.